全文获取类型
收费全文 | 119篇 |
免费 | 2篇 |
国内免费 | 5篇 |
专业分类
妇产科学 | 1篇 |
基础医学 | 5篇 |
临床医学 | 2篇 |
内科学 | 30篇 |
神经病学 | 4篇 |
特种医学 | 2篇 |
外科学 | 38篇 |
综合类 | 5篇 |
预防医学 | 8篇 |
眼科学 | 1篇 |
肿瘤学 | 30篇 |
出版年
2023年 | 1篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2018年 | 6篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 5篇 |
2014年 | 3篇 |
2013年 | 5篇 |
2012年 | 8篇 |
2011年 | 12篇 |
2010年 | 5篇 |
2009年 | 5篇 |
2008年 | 10篇 |
2007年 | 13篇 |
2006年 | 8篇 |
2005年 | 4篇 |
2004年 | 3篇 |
2003年 | 3篇 |
2002年 | 8篇 |
2001年 | 5篇 |
2000年 | 4篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1997年 | 3篇 |
1996年 | 2篇 |
1990年 | 1篇 |
1988年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有126条查询结果,搜索用时 15 毫秒
61.
Brigitte Piso Ingrid Zechmeister Sabine Geiger-Gritsch 《Zeitschrift fur Gesundheitswissenschaften》2011,19(1):73-80
Background
Based on a model of a stepwise approach for decision-making on vaccine introduction, this study aimed to reveal unpublished decision aids, to assess cut-off limits or thresholds for vaccine introduction that have already been used, and to discuss the comprehensiveness and feasibility of our suggested model. 相似文献62.
63.
Güner Z Schmidt U Dahlke MH Schlitt HJ Klempnauer J Piso P 《International journal of colorectal disease》2005,20(2):155-160
Background and aims Surgical improvement can be achieved in selected patients with pseudomyxoma peritonei (PMP) by major cytoreductive surgery and intraperitoneal chemotherapy (IPEC). The purpose of this retrospective study was to analyze morbidity, mortality, and survival following therapy.Patients and methods Between July 1995 and September 2003, 28 patients (mean age 56 years, range 28–79) with PMP were operated on with the aim of complete macroscopical cytoreduction. Surgery was followed by IPEC.Results A macroscopically complete cytoreduction was achieved in 11 patients (40%). The mean operating time was 6 h with a mean of three peritonectomy procedures per patient. Cisplatin (15 out of 28), mitomycin C (6 out of 28) and 5-FU (7 out of 28) were used for the intraoperative chemotherapy. Overall morbidity was 36%. Most frequent surgical complications were digestive fistulae (3 out of 28), abscesses (5 out of 28) and bleeding (2 out of 28). Two patients died postoperatively. Patients with low tumor volume (mean survival time 78±11 vs. 37±9 months, p=0.05) and complete cytoreduction (73±10 vs. 24±8 months, p<0.05) had an improved prognosis.Conclusions Cytoreductive surgery combined with IPEC is associated with acceptable morbidity and mortality. Complete cytoreduction may improve survival, particularly in selected patients with PMP who have a low tumor volume, complete cytoreduction, and no organ metastases.Z. Güner and U. Schmidt contributed equally to this paper 相似文献
64.
Dr. med. univ. DI S. Mathis B. Piso C. Wild 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2010,53(7):733-739
We aimed to depict what could be evidence-based health services planning. Therefore, we performed a literature search on health services planning. The direct use of EBM (evidence-based medicine) and EBP (evidence-based practice) definitions in the context of planning and comparison of the planning process and EBP possible evidence-based processes of acting have been outlined. Definitions of EBM and EBP can partially be applied in the context of health services planning. There is much less established experience in acting evidence-based in planning compared with applications in a clinical setting. The concept of EBP may basically give the direction in health services planning. In detail, it is necessary to adopt EBP principles because of heterogeneous demands for information and also typical characteristics of the health service system. Ways to implement evidence in planning have to be established. 相似文献
65.
P Piso H Bektas U Werner H J Schlitt S Kubicka A Bornscheuer M Manns J Klempnauer 《European journal of surgical oncology》2001,27(3):286-290
AIMS: The prognosis of patients with peritoneal carcinomatosis from gastrointestinal malignancies is poor. The aim of this study was to analyse the results of multimodality treatment for peritoneal carcinomatosis of appendiceal carcinoma. PATIENTS AND METHODS: From 07/95 to 01/00, 17 patients (13 males, 4 female, median age 58 years) underwent peritonectomy procedures in combination with intraperitoneal hyperthermic chemotherapy. Surgical, pathological and survival data were analysed retrospectively. RESULTS: All patients had undergone previous surgical treatment and one patient had received chemotherapy. In all patients peritonectomy procedures, as described by Sugarbaker, were performed with the aim of achieving a macroscopically complete cytoreduction (range 2-6, median 4 procedures per patient). Following resection, open hyperthermic intraperitoneal chemotherapy with cisplatin was performed. Eleven patients had postoperative complications (predominantly "non-surgical") and two patients died postoperatively. The 4-year survival rate was 75%. Complete cytoreducion had a statistically significant positive influence on long-term survival. CONCLUSIONS: In selected patients (WHO status 0/1, minimal residual disease, no distant metastases, complete cytoreduction), the prognosis for patients with peritoneal carcinomatosis of appendiceal origin can be improved by peritonectomy procedures and hyperthermic intraperitoneal chemotherapy. Postoperative morbidity may be increased due to "non-surgical" complications. Copyright Harcourt Publishers Limited. 相似文献
66.
67.
68.
69.
70.
Corneliu Lungoci Aurel Ion Mironiuc Valentin Muntean Traian Oniu Hubert Leebmann Max Mayr Pompiliu Piso 《World journal of gastrointestinal oncology》2016,8(1):67-82
For a long time, treatment of peritoneal metastases (PM) was mostly palliative and thus, this status was link with “terminal status/despair”. The current multimodal treatment strategy, consisting of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), has been strenuously achieved over time, but seems to be the best treatment option for PM patients. As we reviewed the literature data, we could emphasize some milestones and also, controversies in the history of proposed multimodal treatment and thus, outline the philosophy of this approach, which seems to be an unusual one indeed. Initially marked by nihilism and fear, but benefiting from a remarkable joint effort of human and material resources (multi-center and -institutional research), over a period of 30 years, CRS and HIPEC found their place in the treatment of PM. The next 4 years were dedicated to the refinement of the multimodal treatment, by launching research pathways. In selected patients, with requires training, it demonstrated a significant survival results (similar to the Hepatic Metastases treatment), with acceptable risks and costs. The main debates regarding CRS and HIPEC treatment were based on the oncologists’ perspective and the small number of randomized clinical trials. It is important to statement the PM patient has the right to be informed of the existence of CRS and HIPEC, as a real treatment resource, the decision being made by multidisciplinary teams. 相似文献